[
  {
    "ts": null,
    "headline": "Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data",
    "summary": "Eli Lilly  CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in the stock in the wake of its earnings report last week.  Ricks purchased 1,632 shares for an average price of $644.77 on Tuesday, according to a Form 4 report filed with the Securities and Exchange Commission late Tuesday.  Other Lilly insiders purchased stock on Tuesday, including Executive Vice President Daniel Skovronsky.",
    "url": "https://finnhub.io/api/news?id=19b444413d4c62f480a56fa12e4ff753614ed91bc76dbc671dec8b6aa2f7c58e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755036900,
      "headline": "Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data",
      "id": 136328199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in the stock in the wake of its earnings report last week.  Ricks purchased 1,632 shares for an average price of $644.77 on Tuesday, according to a Form 4 report filed with the Securities and Exchange Commission late Tuesday.  Other Lilly insiders purchased stock on Tuesday, including Executive Vice President Daniel Skovronsky.",
      "url": "https://finnhub.io/api/news?id=19b444413d4c62f480a56fa12e4ff753614ed91bc76dbc671dec8b6aa2f7c58e"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
    "url": "https://finnhub.io/api/news?id=9deb48a3b391d5a6975b76a8df57daff12c33f3652ba44ad11599bbf43d26ea9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755028431,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 136322972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index and the Healt",
      "url": "https://finnhub.io/api/news?id=9deb48a3b391d5a6975b76a8df57daff12c33f3652ba44ad11599bbf43d26ea9"
    }
  },
  {
    "ts": null,
    "headline": "These Eli Lilly executives have been scooping up stock after its big drop",
    "summary": "These Eli Lilly executives have been scooping up stock after its big drop",
    "url": "https://finnhub.io/api/news?id=d8a44cfa52d0ea28cb495d778dd6301af9868f620e8ddd73d735bdbacd5c026b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755025620,
      "headline": "These Eli Lilly executives have been scooping up stock after its big drop",
      "id": 136330955,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "These Eli Lilly executives have been scooping up stock after its big drop",
      "url": "https://finnhub.io/api/news?id=d8a44cfa52d0ea28cb495d778dd6301af9868f620e8ddd73d735bdbacd5c026b"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca",
    "url": "https://finnhub.io/api/news?id=44898670113173f3eb11866417ec12fa9fc2e67d687993d71e9d0fda80d82bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755021194,
      "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
      "id": 136322973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca",
      "url": "https://finnhub.io/api/news?id=44898670113173f3eb11866417ec12fa9fc2e67d687993d71e9d0fda80d82bb4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and GSK drive South Korea’s drug licensing activity",
    "summary": "South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.",
    "url": "https://finnhub.io/api/news?id=c4d9e498256f6b035638da7a81b1269db9ee8a01ac938a764e2a4092e19b44d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755020252,
      "headline": "Eli Lilly and GSK drive South Korea’s drug licensing activity",
      "id": 136320454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.",
      "url": "https://finnhub.io/api/news?id=c4d9e498256f6b035638da7a81b1269db9ee8a01ac938a764e2a4092e19b44d0"
    }
  },
  {
    "ts": null,
    "headline": "Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications",
    "summary": "WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly \"bribing\" providers to prescribe its medications.  The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment.  \"Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,\" Attorney General Paxton said.",
    "url": "https://finnhub.io/api/news?id=0eb997f3a56db8dcf82e2f47b79c7207521c8675374ba2e96d9a33829d03de33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755019471,
      "headline": "Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications",
      "id": 136322974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly \"bribing\" providers to prescribe its medications.  The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment.  \"Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme,\" Attorney General Paxton said.",
      "url": "https://finnhub.io/api/news?id=0eb997f3a56db8dcf82e2f47b79c7207521c8675374ba2e96d9a33829d03de33"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade)",
    "summary": "Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to buy. Click for my LLY update.",
    "url": "https://finnhub.io/api/news?id=1e59069592742fda821bed8c3ba04d62eb73899839d1810a028d0aa15c5d9719",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755012056,
      "headline": "Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade)",
      "id": 136321890,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to buy. Click for my LLY update.",
      "url": "https://finnhub.io/api/news?id=1e59069592742fda821bed8c3ba04d62eb73899839d1810a028d0aa15c5d9719"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly",
    "summary": "Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.",
    "url": "https://finnhub.io/api/news?id=57ffee763b6320d47ff71751927d6f006b0b6b56a1e470cdfc257053fff5acb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755011400,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly",
      "id": 136320223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.",
      "url": "https://finnhub.io/api/news?id=57ffee763b6320d47ff71751927d6f006b0b6b56a1e470cdfc257053fff5acb7"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
    "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
    "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009259,
      "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
      "id": 136321094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148319783/image_2148319783.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
      "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3"
    }
  },
  {
    "ts": null,
    "headline": "If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today",
    "summary": "The biopharmaceutical company has an exciting lead compound in development.",
    "url": "https://finnhub.io/api/news?id=f28d471badcfeee3d2cd64c1c12a488e465c9a0102005d170dab0439511536a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755008760,
      "headline": "If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today",
      "id": 136320458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The biopharmaceutical company has an exciting lead compound in development.",
      "url": "https://finnhub.io/api/news?id=f28d471badcfeee3d2cd64c1c12a488e465c9a0102005d170dab0439511536a5"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason to Buy Eli Lilly (LLY) Stock",
    "summary": "There's a reason you might want to hold off on buying Lilly stock.",
    "url": "https://finnhub.io/api/news?id=0bb4d315da7b175a4e7f7914c85335557b53605c1b2501cd1389cb19849f4298",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755006300,
      "headline": "1 Reason to Buy Eli Lilly (LLY) Stock",
      "id": 136320459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There's a reason you might want to hold off on buying Lilly stock.",
      "url": "https://finnhub.io/api/news?id=0bb4d315da7b175a4e7f7914c85335557b53605c1b2501cd1389cb19849f4298"
    }
  },
  {
    "ts": null,
    "headline": "If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today",
    "summary": "Eli Lilly stock plummeted after its recent earnings report, but it's been a long-term winner for investors.",
    "url": "https://finnhub.io/api/news?id=1dcbca4fdcb754d33c5a6be13840bb86038c437384e30e6f7f934c1eee39c21a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754999940,
      "headline": "If You'd Invested $1,000 in Eli Lilly (LLY) Stock 5 Years Ago, Here's How Much You'd Have Today",
      "id": 136315973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock plummeted after its recent earnings report, but it's been a long-term winner for investors.",
      "url": "https://finnhub.io/api/news?id=1dcbca4fdcb754d33c5a6be13840bb86038c437384e30e6f7f934c1eee39c21a"
    }
  },
  {
    "ts": null,
    "headline": "US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche",
    "summary": "The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include h",
    "url": "https://finnhub.io/api/news?id=f707ee98921e7e078140073abaf19d858e85f133b0fb14b0b53be51653626a1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754991120,
      "headline": "US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche",
      "id": 136315974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The United States Personalized Medicine Market is projected to soar to US$ 307.04 billion by 2033 from US$ 169.56 billion in 2024, experiencing a CAGR of 6.82% from 2025 to 2033. Key growth drivers include advances in next-generation sequencing, rising demand for customized treatments, and government policy support. The integration of technologies like AI and machine learning is enhancing precision in diagnostics and treatment, revolutionizing personalized healthcare. Market challenges include h",
      "url": "https://finnhub.io/api/news?id=f707ee98921e7e078140073abaf19d858e85f133b0fb14b0b53be51653626a1b"
    }
  },
  {
    "ts": null,
    "headline": "2 All-American Dividend Gems To Buy Before The Market Wakes Up",
    "summary": "Explore how economic struggles mirror broad market challenges.",
    "url": "https://finnhub.io/api/news?id=f8bc2a956acf0c206e6cb751d4475a593cf13460a5a5f57cad0453e27dd05e8f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754983800,
      "headline": "2 All-American Dividend Gems To Buy Before The Market Wakes Up",
      "id": 136315475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154515143/image_2154515143.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore how economic struggles mirror broad market challenges.",
      "url": "https://finnhub.io/api/news?id=f8bc2a956acf0c206e6cb751d4475a593cf13460a5a5f57cad0453e27dd05e8f"
    }
  },
  {
    "ts": null,
    "headline": "LLY Q2 Deep Dive: Weight Loss Pill Data and Channel Dynamics Spur Investor Uncertainty",
    "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 37.6% year on year to $15.56 billion. The company’s full-year revenue guidance of $61 billion at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $6.31 per share was 12.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=f593f27e1df493fbe39f435d68b0614060d2483729d0d380634aa35409381e7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754983580,
      "headline": "LLY Q2 Deep Dive: Weight Loss Pill Data and Channel Dynamics Spur Investor Uncertainty",
      "id": 136315975,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 37.6% year on year to $15.56 billion. The company’s full-year revenue guidance of $61 billion at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $6.31 per share was 12.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=f593f27e1df493fbe39f435d68b0614060d2483729d0d380634aa35409381e7e"
    }
  },
  {
    "ts": null,
    "headline": "GARP: Quality Can Help Flourish In Bullish Conditions",
    "summary": "GARP: Quality Can Help Flourish In Bullish Conditions",
    "url": "https://finnhub.io/api/news?id=2c47452a93821f60312b019b1abc6f53e5fad44fb4e0a09573afdc6307f59c6b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754983071,
      "headline": "GARP: Quality Can Help Flourish In Bullish Conditions",
      "id": 136315411,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2c47452a93821f60312b019b1abc6f53e5fad44fb4e0a09573afdc6307f59c6b"
    }
  },
  {
    "ts": null,
    "headline": "3 ways the GLP-1 market has changed shape this year",
    "summary": "Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.",
    "url": "https://finnhub.io/api/news?id=5cd60b1fcb642e4060dad209b10108f0dae6f2f52481949c97519affc427d533",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754981865,
      "headline": "3 ways the GLP-1 market has changed shape this year",
      "id": 136315976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.",
      "url": "https://finnhub.io/api/news?id=5cd60b1fcb642e4060dad209b10108f0dae6f2f52481949c97519affc427d533"
    }
  },
  {
    "ts": null,
    "headline": "Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise",
    "summary": "Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.",
    "url": "https://finnhub.io/api/news?id=18e0825ddcf3a73b36aaf4db3edfe28c1dc6e27844d9a3c8b70ef5ce0c7c83b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754981858,
      "headline": "Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise",
      "id": 136315977,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biotechs are coming to the island as tariffs threaten overseas drug exports, and finding Puerto Rico is more than just a leading manufacturing hub.",
      "url": "https://finnhub.io/api/news?id=18e0825ddcf3a73b36aaf4db3edfe28c1dc6e27844d9a3c8b70ef5ce0c7c83b0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Mounjaro Exhibits Heart Benefits In Type 2 Diabetes Landmark Trial",
    "summary": "Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,000 adults with cardiovascular […]",
    "url": "https://finnhub.io/api/news?id=72096fa83c60b563fbc8514bca5321dbc8b64d5dda717e4b07c661dc0aaa1fae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754957921,
      "headline": "Lilly’s Mounjaro Exhibits Heart Benefits In Type 2 Diabetes Landmark Trial",
      "id": 136315978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,000 adults with cardiovascular […]",
      "url": "https://finnhub.io/api/news?id=72096fa83c60b563fbc8514bca5321dbc8b64d5dda717e4b07c661dc0aaa1fae"
    }
  }
]